
usd may pm et
summari provid medic product servic primarili area orthoped
medic surgic medsurg well neurotechnolog spine
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
may pm stock trade
prior widespread concern
anticip sale growth
billion follow growth
mid-may expect sale declin
yoy billion due advers
impact elect procedur volum
 follow strong rebound
sale billion
despit merger integr activ recent
year expand oper margin
year year novemb agre
acquir enterpris valu
think chose opportun
time acquir share
beaten distributor issu
liquid concern think
achiev basi point margin
expans exclud impact
acquisit expect close
anticip continu competit
strength syk mako robot continu
drive share gain tradit
stabl knee hip replac market
approxim mako
placement competit account
believ share trade
ep attract valu although
disrupt hurt near-term
result think well posit
take market share
coronaviru recess strength
robot orthoped offer mako system
high exposur outpati procedur
believ chronic progress
natur condit impact patient
support strong rebound procedur volum
restrict eas recent
year competit foot
aid weak primari
competitor zimmer biomet
pend acquisit
substanti bolster presenc
extrem procedur opinion
risk recommend target price
includ slower-than-expect recoveri
intensifi competit failur integr
acquisit prolong weak
target reflect
multipl ep estim
oper competit area global
medic devic industri character rapid
technolog innov market share volatil
medical/surg suppli unit may vulner
reduct hospit capit equip spend
demand orthoped product becom
less immun econom cycl
jul ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
vice-president global
corpor overview corp lead medic technolog compani offer innov
product servic orthopaed revenu medic surgic
neurotechnolog spine
orthopaed segment consist primarili implant use hip knee joint replac
trauma extrem surgeri syk goal deliv advanc implant design special
instrument make orthopaed surgeri recoveri simpler faster effect artifici
joint implant patient whose natur joint damag arthriti osteoporosi
diseas injuri also sell trauma-rel product use primarili fixat fractur
result sudden injuri key growth driver recent year mako robot orthoped
system first receiv fda approv total knee applic year-end mako
offer three applic support partial knee total hip total knee procedur global
instal base mako system approxim mako knee procedur increas yoy
total mako procedur reach one four lead global competitor
joint replac trauma extrem product three
inc depuy synth johnson johnson compani smith nephew plc
medic surgic medsurg segment product includ surgic equip navig
system instrument endoscop commun system endoscopi patient handl
emerg medic equip intens care dispos product medic reprocess
remanufactur medic devic sustain medic devic product use varieti
medic specialti mani competitor medsurg segment instrument
sub-seg acquir safeair ag swiss medic devic compani dedic design develop
manufactur innov surgic smoke evacu solut also endoscopi
sub-seg launch advanc imag modal platform next gener syk
neurotechnolog spine product includ neurosurg neurovascular spinal implant devic
syk neurotechnolog offer includ product use minim invas endovascular techniqu
comprehens line product tradit brain open skull base surgic procedur
orthobiolog biosurgeri product includ synthet bone graft vertebr augment
product minim invas product treatment acut ischem hemorrhag stroke
one five lead global competitor neurotechnolog four johnson
 johnson terumo corpor also one five lead global competitor spine
four sofamor danek inc subsidiari depuy synth
globu medic
corpor strategi seek achiev sale growth high-end medic technolog
med-tech industri maintain capit alloc strategi priorit acquisit
dividend share repurchas invest million acquisit paid million
dividend repurchas million share success acquisit
tend small rel market capit
impact major develop novemb announc enter definit
agreement acquir per share equiti valu reflect
premium wmgi price market close novemb well-posit support
wmgi busi due strength syk commerci organ financi well-being howev
believ could regulatori pushback deal may requir asset divestitur
appeas expect deal close
novemb acquir global leader complex spine minim
invas solut billion februari acquir entellu medic medic technolog
compani make product design minim invas treatment variou ear nose throat
diseas state million septemb acquir novadaq technolog inc lead
develop fluoresc imag million
august initi voluntari product recal involv specif lot product
respons warn letter receiv food drug administr fda resum
ship product return full suppli capac end product manufactur
intens care dispos product acquir billion
financi trend syk sale grew yoy billion reflect compound annual
growth rate compound-annual-growth-rate includ benefit sever acquisit incur
research develop expens million revenu rate
compani incur preced five year decemb quarter
moder net debt total capit ratio low leverag debt ebitda ratio
gener posit free cash flow least past five year billion given syk
financi posit dont see near-term difficulti compani pursu strategi
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc may technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neg
recess concern although
medic devic sub-industri
histor defens recess resist
nonetheless expect near-term result
wors recent year despit neg
outlook think medic devic compani
fare much better compani
industri health care essenti
peopl expect
neg impact global procedur volum
procedur volum could quickli return
worst diseas impact pass
continu achiev robust organ growth
 mid-to-high single-digit revenu growth
driven new product grow
emerg market exposur howev expect
revenu neg impact
basi point result
mean anticip organ growth
low-single-digit
long run gener see posit
fundament trend medic devic
demand cost-effect value-bas health
care age popul rise outlay
result steadi flow
innov product revenu growth
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much commentari
around introduct mdr reason
believ new regul could
neg impact industri exampl
juli submit letter
world trade organ request
mdr ivdr delay three year also
novemb european medic devic
trade associ critic slow
piecem implement new
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
prior concern expect
industri earn rise low-double-digit
percentag driven sale new product
command higher margin expect
industri earn rise mid-single-digit
percentag origin project
industri oper ebit margin
estim margin
think margin
like flat year-over-year
year date march health
equip sub-index declin
vs declin
composit index health
increas valu
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
deal expect close /kevin huang cfa
et cfra keep buy opinion share stryker corpor
lift target price base
multipl ep estim multipl
exce rang due strengthen
competit posit orthoped market ep vs
land higher estim lift ep
ep sale grew organ
billion organ basi orthopaed sale grew yoy medsurg
neurotechnolog spine impress mako robot
placement made expect placement
prior-year period meanwhil mako total knee arthroplasti
procedur increas yoy call manag express
confid achiev continu low double-digit earn growth
sum impress quarter live high expect
reiter buy opinion /kevin huang cfa
et cfra reiter buy opinion share stryker corpor
lift target base multipl
ep multipl peer
sustain above-market organ growth driven increasingli strong
competit posit ep vs higher
estim lift ep ep
sale grew organ billion organ
basi orthopaed sale grew yoy medsurg neurotechnolog
spine continu see market share gain knee replac
driven mako robot sale increas robot util believ
success mako knee procedur enabl compani achiev
share gain histor stabl hip replac market mako hip
procedur grew doubl digit total mako procedur grew
approxim year-over-year approxim led
growth mako knee procedur /kevin huang cfa
analyst research note compani news
pm et cfra lower opinion share stryker corpor buy
strong buy follow recent share price appreci
share trade closer target price
lower opinion buy strong buy continu view
share attract valu compani well posit take
market share coronaviru recess strength
robot orthoped offer mako system high exposur
et cfra reaffirm strong buy opinion share
corpor lower target price
base multipl ep estim ep
vs surpass consensu expect lower ep
estim ep april
saw sale declin vs prior-year level in-lin
peer see howev sound notic bullish
elect procedur recoveri peer note chronic progress
natur condit impact syk patient support strong rebound
addit experienc increas demand across almost entireti
medic busi syk revenu due given
global revenu elect enact
numer cost control like place remaind
continu favor view syk valuat recent level
pm et cfra lift opinion share stryker corpor strong
buy buy lower target price
reflect anticip advers impact
compani valu lower ep estim
updat price target reflect forward price-to-earnings ratio ep
februari see upsid potenti share believ
investor overpr impact syk valuat
et cfra reaffirm buy opinion share stryker corpor
rais target price base
multipl ep estim multipl exce
syk rang due syk strengthen
competit posit orthoped market ep vs beat
estim lower ep
initi ep organ basi sale grew yoy
expect syk out-performance driven sustain
strength knee growth extrem strong placement mako
robot global vs despit
fda approv zimmer biomet rosa knee system approxim
mako placement competit account
think well-posit continu take market
share hip knee replac market still expect
close acquisit /kevin huang cfa
et cfra keep hold opinion share
morn announc enter definit
agreement acquir per share
reflect premium price market close novemb
merger would significantli boost market share orthoped
product extrem surgeri particularli upper extrem
shoulder elbow wrist hand procedur think chosen
opportun time acquir share beaten
recent distributor issu liquid concern well-posit
support busi due strength commerci organ
financi well-being howev believ could regulatori
pushback deal may requir asset divestitur appeas lift
price target share reflect announc
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
